Dana-Farber Cancer Institute
@danafarber.bsky.social
A leading center for expert, compassionate cancer care and advanced research.
Appts: 877-442-3324 | http://dana-farber.org
Appts: 877-442-3324 | http://dana-farber.org
Menin inhibitors are a promising new class of drugs for acute leukemias. Richard Stone, MD, provides an update on our impact and ongoing clinical research efforts to advance menin inhibitor therapies for acute leukemias, aiming for effective and potentially all-oral treatments: bit.ly/4qL0b2S
November 11, 2025 at 4:00 PM
Menin inhibitors are a promising new class of drugs for acute leukemias. Richard Stone, MD, provides an update on our impact and ongoing clinical research efforts to advance menin inhibitor therapies for acute leukemias, aiming for effective and potentially all-oral treatments: bit.ly/4qL0b2S
During Pancreatic Cancer Awareness Month, we’re highlighting new research from Dana-Farber, @mit.edu, and the @broadinstitute.org revealing potential new ways to harness the immune system against pancreatic cancer. Learn more: bit.ly/3Wt0qBN
November 10, 2025 at 6:00 PM
During Pancreatic Cancer Awareness Month, we’re highlighting new research from Dana-Farber, @mit.edu, and the @broadinstitute.org revealing potential new ways to harness the immune system against pancreatic cancer. Learn more: bit.ly/3Wt0qBN
Congratulations to Olive Sturtevant, MHP, MT(ASCP), SBB, SLS, ASQ (CQA), of our Connell and O'Reilly Families Cell Manipulation Core Facility and recipient of the AABB's 2025 President's Award for her extraordinary dedication and service.
November 7, 2025 at 2:30 PM
Congratulations to Olive Sturtevant, MHP, MT(ASCP), SBB, SLS, ASQ (CQA), of our Connell and O'Reilly Families Cell Manipulation Core Facility and recipient of the AABB's 2025 President's Award for her extraordinary dedication and service.
New research published in @natchembio.nature.com by @danafarber.bsky.social’s William Gibson, MD, PhD, reveals a general strategy for TP53 missense mutant cancers (majority) with prototype small molecules. @broadinstitute.org
Read more at bit.ly/4onnFJO
Read more at bit.ly/4onnFJO
November 6, 2025 at 7:30 PM
New research published in @natchembio.nature.com by @danafarber.bsky.social’s William Gibson, MD, PhD, reveals a general strategy for TP53 missense mutant cancers (majority) with prototype small molecules. @broadinstitute.org
Read more at bit.ly/4onnFJO
Read more at bit.ly/4onnFJO
The @fda.gov approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory acute myeloid leukemia (AML) with NPM1 gene mutations. Learn more: bit.ly/3WEexnN
November 5, 2025 at 1:30 PM
The @fda.gov approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory acute myeloid leukemia (AML) with NPM1 gene mutations. Learn more: bit.ly/3WEexnN
What happens when targeted therapy meets radiation therapy? Learn about the exciting and innovative form of medicine called radioligand therapy: bit.ly/47vXrxy
November 3, 2025 at 11:00 PM
What happens when targeted therapy meets radiation therapy? Learn about the exciting and innovative form of medicine called radioligand therapy: bit.ly/47vXrxy
Back in 2014, there were no targeted therapies approved for childhood brain cancers. Now there are a few, with more on the radar – almost all of which have deep roots in our science. Learn more about how our research is advancing treatment for childhood brain cancer: bit.ly/47hUQZd
October 31, 2025 at 2:00 PM
Back in 2014, there were no targeted therapies approved for childhood brain cancers. Now there are a few, with more on the radar – almost all of which have deep roots in our science. Learn more about how our research is advancing treatment for childhood brain cancer: bit.ly/47hUQZd
Please join us for a webinar on What to Know About Lung Cancer.
Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology will share insights on prevention, early detection, and the latest treatment advancements, followed by a Q&A. Register here: bit.ly/3L9ZmjA
Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology will share insights on prevention, early detection, and the latest treatment advancements, followed by a Q&A. Register here: bit.ly/3L9ZmjA
October 30, 2025 at 1:30 PM
Please join us for a webinar on What to Know About Lung Cancer.
Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology will share insights on prevention, early detection, and the latest treatment advancements, followed by a Q&A. Register here: bit.ly/3L9ZmjA
Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology will share insights on prevention, early detection, and the latest treatment advancements, followed by a Q&A. Register here: bit.ly/3L9ZmjA
In a ‘Challenge your Expert’ session, Paula Ugalde, MD, discusses how highly effective neoadjuvant therapies are reshaping the definition of lung cancer resectability, offering new treatment possibilities for patients. #ESMO25
October 20, 2025 at 9:02 AM
In a ‘Challenge your Expert’ session, Paula Ugalde, MD, discusses how highly effective neoadjuvant therapies are reshaping the definition of lung cancer resectability, offering new treatment possibilities for patients. #ESMO25
Erica Mayer, MD, MPH, delivers patient-reported data supporting SERENA-6 treatment approach to optimize outcomes and improve quality of life for patients with advanced breast cancer. #ESMO25
October 20, 2025 at 8:36 AM
Erica Mayer, MD, MPH, delivers patient-reported data supporting SERENA-6 treatment approach to optimize outcomes and improve quality of life for patients with advanced breast cancer. #ESMO25
Thomas Hwang, MD, explores the magnitude of clinical benefits of cancer medicines in curative settings and the assessment of health decisions across Europe. #ESMO25
October 20, 2025 at 8:25 AM
Thomas Hwang, MD, explores the magnitude of clinical benefits of cancer medicines in curative settings and the assessment of health decisions across Europe. #ESMO25
We’re back for day four of #ESMO25. Follow along here and with @danafarbernews.bsky.social as continue to learn and explore the latest in oncology care and research: bit.ly/478Z1qh
October 20, 2025 at 8:02 AM
We’re back for day four of #ESMO25. Follow along here and with @danafarbernews.bsky.social as continue to learn and explore the latest in oncology care and research: bit.ly/478Z1qh
Erica Mayer, MD, MPH, highlights evolving endocrine treatment strategies for HR-positive breast cancer and how front-line advances are moving into earlier stages of care on panel with @drsarahsammons.bsky.social. #ESMO25
October 19, 2025 at 4:46 PM
Erica Mayer, MD, MPH, highlights evolving endocrine treatment strategies for HR-positive breast cancer and how front-line advances are moving into earlier stages of care on panel with @drsarahsammons.bsky.social. #ESMO25
Filipa Lynce, MD, shares insights on tailoring breast cancer care for special populations, highlighting strategies to ensure personalized and equitable treatment for all patients. #ESMO25
October 19, 2025 at 3:36 PM
Filipa Lynce, MD, shares insights on tailoring breast cancer care for special populations, highlighting strategies to ensure personalized and equitable treatment for all patients. #ESMO25
Filipa Lynce, MD, shares insights on tailoring breast cancer care for special populations, highlighting strategies to ensure personalized and equitable treatment for all patients. #ESMO25
October 19, 2025 at 3:35 PM
Filipa Lynce, MD, shares insights on tailoring breast cancer care for special populations, highlighting strategies to ensure personalized and equitable treatment for all patients. #ESMO25
@drchoueiri.bsky.social co-chairs today’s Presidential Symposium, welcoming the estimated 9,000 people in the room. #ESMO25
October 19, 2025 at 2:58 PM
@drchoueiri.bsky.social co-chairs today’s Presidential Symposium, welcoming the estimated 9,000 people in the room. #ESMO25
Joaquim Bellmunt, MD, PhD, highlights the mechanism of action, efficacy, and safety profile of antibody-drug conjugates in bladder cancer. #ESMO25
October 19, 2025 at 1:33 PM
Joaquim Bellmunt, MD, PhD, highlights the mechanism of action, efficacy, and safety profile of antibody-drug conjugates in bladder cancer. #ESMO25
Alicia Morgans, MD, MPH, moderates a discussion on advancing personalized care for prostate cancer, exploring patient-centered solutions for metastatic hormone-sensitive and non-metastatic castration-resistant prostate cancer. #ESMO25
October 19, 2025 at 11:32 AM
Alicia Morgans, MD, MPH, moderates a discussion on advancing personalized care for prostate cancer, exploring patient-centered solutions for metastatic hormone-sensitive and non-metastatic castration-resistant prostate cancer. #ESMO25
Erica Pimenta, MD, PhD, explores opportunities for how GLP-1 based medicines – commonly used for diabetes and weight management – could play a role in cancer prevention and treatment. #ESMO25
October 19, 2025 at 9:08 AM
Erica Pimenta, MD, PhD, explores opportunities for how GLP-1 based medicines – commonly used for diabetes and weight management – could play a role in cancer prevention and treatment. #ESMO25
@guinadermarta.bsky.social takes part in the ESMO Resilience Task Force Open Forum, highlighting strategies to co-create a resilient oncology workforce and support clinician well-being. #ESMO25
October 19, 2025 at 8:47 AM
@guinadermarta.bsky.social takes part in the ESMO Resilience Task Force Open Forum, highlighting strategies to co-create a resilient oncology workforce and support clinician well-being. #ESMO25
Paul Nguyen, MD, MBA, presents results from the ENZARAD trial – examining whether adding enzalutamide to standard hormone + radiation therapy can improve outcomes for people with high-risk prostate cancer. #ESMO25
October 19, 2025 at 8:25 AM
Paul Nguyen, MD, MBA, presents results from the ENZARAD trial – examining whether adding enzalutamide to standard hormone + radiation therapy can improve outcomes for people with high-risk prostate cancer. #ESMO25
Based on results from three clinical trials, Marc Machaalani, MD, shares new findings of how MAdCAM-1 helps predict outcomes for people with metastatic renal cell carcinoma. #ESMO25
October 19, 2025 at 8:01 AM
Based on results from three clinical trials, Marc Machaalani, MD, shares new findings of how MAdCAM-1 helps predict outcomes for people with metastatic renal cell carcinoma. #ESMO25